Orlistat and cardiovascular risk profile in hypertensive patients with metabolic syndrome: the ARCOS study

A perda de peso melhora as anormalidades metabólicas e reduz o risco cardiovascular em pacientes obesos hipertensos. Com o objetivo de avaliar o impacto da perda de peso mantida sobre o risco coronariano, submetemos 181 pacientes hipertensos com síndrome metabólica à terapia com orlistat, 120 mg, tr...

Full description

Bibliographic Details
Main Author: Zanella, Maria Teresa [UNIFESP] (author)
Other Authors: Uehara, Marcelo Hiroshi [UNIFESP] (author), Ribeiro, Artur Beltrame [UNIFESP] (author), Bertolami, Marcelo (author), Falsetti, Ana Claudia (author), Yunes, Mirela A. (author)
Format: article
Language:eng
Published: 2015
Subjects:
Obesidade central
Orlistat
Redução de peso
Risco cardiovascular
Score de risco de Framingham
Central obesity
Weight reduction
Cardiovascular risk
Framingham risk score
Online Access:https://doi.org/http://dx.doi.org/10.1590/S0004-27302006000200023
https://doi.org/10.1590/S0004-27302006000200023
Country:Brazil
Oai:oai:k-repositorio.unifesp.br:11600/3047

Internet

https://doi.org/http://dx.doi.org/10.1590/S0004-27302006000200023
https://doi.org/10.1590/S0004-27302006000200023

Similar Items